Transcatheter Aortic Valve Replacement (TAVR): A Comprehensive Descriptive Analysis.

Area of Science:

• Cardiovascular Medicine
• Interventional Cardiology
• Health Services Research

Background:

• Transcatheter Aortic Valve Replacement (TAVR) is a minimally invasive procedure for severe aortic stenosis, particularly for high-risk patients.
• The increasing adoption of TAVR in lower-volume institutions raises questions about outcome comparability with established high-volume centers.

Purpose of the Study:

• To analyze procedural volume and patient outcomes for TAVR at a specific healthcare institution.
• To compare institutional outcomes with results from the landmark PARTNER III trial.
• To evaluate TAVR-related complications and assess patient selection criteria.

Main Methods:

• A retrospective descriptive study design was employed.
• Data from 37 patients who underwent TAVR in 2022 at a public, multi-institutional healthcare system were analyzed.
• Outcomes including mortality, readmission rates, and cardiovascular/cerebrovascular complications at 30 days and 1 year were collected and compared to the PARTNER III trial.

Main Results:

• No 30-day mortality was observed, contrasting with 1% in the PARTNER III trial.
• The 1-year mortality rate was 2.7%, significantly lower than the 8.5% reported in the PARTNER III trial.
• Zero patients experienced 30-day readmission for valve-related issues.

Conclusions:

• Lower-volume healthcare institutions can achieve TAVR outcomes comparable to higher-volume centers.
• These findings challenge the notion that superior outcomes are solely dependent on institutional size.
• Quality of care, teamwork, and individualized patient management are critical for excellent clinical outcomes in TAVR, irrespective of institutional volume.